ATB-810

ATB-810
Product Description

ATB-810 is a first-in-class antisense oligonucleotide (ASO) candidate for the treatment of ALS and progressive multiple sclerosis. Powered by Autotelic Bio’s proprietary C-Duplex™ technology, it is designed to achieve broad brain distribution and improved tolerability, with compelling efficacy demonstrated in preclinical neurodegenerative disease models.

Read more Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Autotelic Bio (2)

  • ATB-101

    Product ATB-101

    ATB-101 is the world’s first fixed-dose combination of olmesartan and dapagliflozin, designed for patients with hypertension and type 2 diabetes. A Phase 3 study has been completed in Korea, with regulatory approval expected in Q1 2027. U.S. development is progressing through the FDA 505(b)(2) pathway, wit...
  • ATB-720

    Product ATB-720

    ATB-720 is a first-in-class topical antisense oligonucleotide (ASO) candidate for atopic dermatitis. Designed to deliver targeted activity directly to the skin while minimizing systemic exposure, ATB-720 has demonstrated compelling preclinical efficacy and offers a novel, non-steroidal treatment approach.